For a clinical-stage biotech, every hiring decision is a runway decision. A clinical project manager in Poland, a regulatory lead in Germany, or a biostatistician in Portugal can move a Phase II program forward by months, but only if the company can pay them legally without spending six months and tens of thousands of dollars opening a local entity, and without pre-funding a year of payroll out of a Series A that has to last 24 months.
That is the practical problem an Employer of Record (EOR) solves for biotech. This article walks through the 2025 to 2026 capital environment, why entity setup is the wrong default for most clinical-stage companies, the specific pre-funded-payroll trap that ambushes finance teams, the four roles biotechs hire abroad most often, when to graduate to an owned entity, and what a CFO should ask an EOR before signing.
It is a companion piece to the hub article on why medical companies use EOR. Read that first if you want the broader sector picture.
The 2025 to 2026 biotech capital environment
The hiring strategy follows the cash. The cash picture for small-cap biotech in 2025 was bifurcated and, for most companies, tight.
Silicon Valley Bank's mid-year report noted that first-half 2025 biopharma deal value held up against 2024, but the median Series A was carrying fewer hires per dollar and the IPO window stayed narrow. The J.P. Morgan Healthcare Conference in January 2026 reinforced the same theme: investors want longer runway and more capital-efficient operating plans.
Public 10-Ks tell the story role by role. Recursion Pharmaceuticals' 2024 10-K details a workforce distributed across the US, Canada, and the UK, exactly the pattern an EOR enables. Relay Therapeutics' filings and Vor Biopharma's 8-K disclosures on workforce reductions show how quickly headcount plans flex when a trial reads out, another argument against locking capital into entity setup.
Layered on top is consolidation pressure at the top of the market. Novo Nordisk's announced 9,000 cuts, Merck's 6,000-role program, and Bayer's 12,000+ cumulative reductions since 2023 mean a deeper bench of unattached specialists worldwide. Smaller biotechs that can hire across borders quickly are picking up senior people who would have been unreachable two years ago.
The takeaway: the 2025 to 2026 environment rewards biotechs that can convert dollars into hires fast, in any country where the right person happens to live, without carrying entity overhead they may not need in 18 months.
Why entity setup is usually wrong for a clinical-stage biotech
Opening a foreign legal entity sounds clean. In practice, for a company that has not yet read out a pivotal trial, it is a poor capital allocation.
The numbers vary by jurisdiction, but a typical pattern looks like this:
- Three to nine months from kickoff to a working entity with payroll, banking, and benefits provisioning.
- $15,000 to $50,000+ in setup legal, registration, and provider fees, with Germany, Switzerland, and Japan at the upper end.
- Recurring annual cost of local accounting, statutory filings, and a payroll provider, which in a single-employee country often exceeds the loaded cost of using an EOR.
- Wind-down cost if a trial fails, a partnership shifts, or the program pivots, and biotech timelines pivot more than most.
The OECD's Taxing Wages data and country statistical agencies confirm that the loaded cost of employment in most EU jurisdictions runs 20 to 35% above gross salary once social contributions and statutory benefits are included. None of that goes away with an entity. What an entity adds is fixed overhead, useful only if the country has a long-term, multi-employee plan.
For a Series A or B biotech making its first one to three hires in a country, EOR is almost always cheaper, faster, and reversible.
The pre-funded payroll trap
This is the line item biotech CFOs miss most often, and it shows up exactly when cash is tightest.
Several legacy EOR providers require the client to pre-fund the upcoming month's payroll into a holding account before salaries are paid. For a US-only company hiring its first five international employees at a blended $120K, that is on the order of $50,000 sitting outside the operating account at all times, plus employer contributions. For a 30-person international team it scales to a permanent six- or seven-figure restricted balance.
In a normal SaaS business that is annoying. In a clinical-stage biotech with 18 months of runway it is a structural problem. Restricted cash does not extend the runway. It does not earn investor returns. It does not pay for a manufacturing slot. It sits there, against the day the EOR debits it.
The alternative is an EOR that invoices in arrears: pay employees, then bill the client for the same period plus the per-employee fee. The cash stays on the balance sheet and earns whatever the company earns on it until payment terms come due. Borderless AI's healthcare offering is built on this model: payroll runs without requiring pre-funded salary deposits, and Borderless invoices the client after the fact rather than holding salary in trust.
For a finance leader watching every dollar against the next data readout, this is one of the more material differences between EOR providers, and one of the easiest to overlook in a vendor demo.
Four roles biotechs most commonly hire via EOR
International hiring at a clinical-stage biotech tends to concentrate in a small number of roles where the talent pool genuinely is global, the work is remote-compatible, and the unit economics of EOR are obviously better than entity setup.
1. Clinical research associate (CRA). The single highest-volume EOR role in life sciences. CRAs sit at the intersection of trial site management and sponsor oversight; their work is field-based, region-specific, and follows trial geography rather than the sponsor's headquarters. Common EOR jurisdictions are Poland, Portugal, Spain, Mexico, Brazil, and India, where major CROs such as Parexel run regional hubs. For a sponsor running a 50-site Phase II across Central Europe, hiring two senior CRAs through an EOR is the difference between an enrollment timeline that holds and one that slips.
2. CMC and quality. Chemistry, manufacturing, and controls roles cluster around contract manufacturers in specific geographies. Switzerland, Germany, Ireland, and increasingly India for biologics. The talent rarely relocates, and quality assurance roles (EU GMP-aligned) need to live close to the manufacturing site. EOR allows a biotech to attach a senior QA lead in Basel or Cork without standing up a Swiss or Irish entity for one or two people.
3. Regulatory affairs. EU MDR and IVDR for medical devices, and the EMA centralised procedure for therapeutics, mean European regulatory talent has to be physically European. Germany, Ireland, the Netherlands, and Switzerland dominate. Regulatory affairs is also a role where 1099 contracting fails the DOL economic-realities test almost every time. The work is too integrated, too directed, and too sustained to be genuinely independent. EOR is the clean route.
4. Biostatistics and SAS programming. A remote-native specialty with deep talent pools in India, Poland, Romania, and Portugal. Many small biotechs use a mix of CRO-supplied biostats and one or two in-house biostatisticians who own the SAP and key analyses. The in-house hires are almost always EOR.
For a more detailed breakdown of CRA hiring specifically, see the companion guide on hiring CRAs globally.
When to graduate to an owned entity
EOR is rarely permanent for a successful biotech. The decision to open an entity tends to track three thresholds.
Headcount. Once a country crosses roughly 10 to 20 employees, the recurring per-employee EOR fee usually exceeds the fixed cost of running a local entity with a payroll provider and external accountant. The exact crossover depends on the country, the loaded cost, and how aggressively the EOR has discounted volume.
Strategic permanence. A Series C biotech preparing for IPO, or one that has signed a long-term lease and is hiring a country GM, has effectively made a permanent commitment. At that point, owning the employment relationship matters for IP control, equity administration, and signaling to local talent that the company is real.
IPO and S-1 prep. Auditors and underwriters look hard at the legal structure underneath disclosed headcount. Most biotechs preparing an S-1 will rationalize the international footprint either by spinning up entities in the two or three largest-population countries or by consolidating EOR-employed staff in a smaller set of jurisdictions. The SEC's S-1 disclosure requirements do not prohibit EOR-employed staff, but the structure has to be cleanly described.
The practical sequence most biotechs follow: EOR for the first two to five hires per country, monitor headcount and trial trajectory, open an entity in the country once the team passes ~15 people or once a strategic decision is made to plant a flag. EOR continues to cover the long tail of single-employee countries indefinitely. Borderless's 100%-owned entity model across 170+ countries means the migration path is to a known counterparty rather than a third-party aggregator.
What a biotech CFO should ask an EOR before signing
Most EOR sales conversations focus on country coverage. For a capital-constrained biotech, the more important questions are operational and financial.
- Do you require pre-funded payroll, or do you invoice in arrears? This is the single biggest cash question. Get the answer in writing before the master service agreement.
- Do you own your entities in the countries we're hiring into, or do you partner with a local provider? Owned entities shorten the chain between the client, the worker, and any compliance event. Aggregator models add a second legal employer and can lag on terminations, equity events, and onboarding changes. Verify the entity ownership for the specific countries you need, not just the headline coverage map.
- What is the loaded cost in each country, broken out? Gross salary, employer social contributions, statutory benefits, supplemental benefits, and the EOR fee should be itemized. The SHRM benchmark guidance is a useful sanity check. Watch for EORs that quote a single blended percentage without showing the components.
- How do you handle equity, RSUs, and ISOs across jurisdictions? Employee equity is one of the harder cross-border problems. Tax treatment of options varies by country and changes regularly. The provider should have specific answers for the countries you care about, not a generic "we support equity."
- What happens if a trial fails and we need to terminate quickly? Termination rules vary sharply. Germany, France, and Brazil are restrictive; the UK and Singapore less so. Ask for the typical notice period, severance exposure, and provider response time for terminations in each target country.
- Sanctions, GxP, and data handling. OFAC sanctions screening, GxP-relevant background verification, and GDPR-compliant data handling should be standard. Confirm in writing.
- What is the path from EOR to owned entity? When the company is ready to graduate, can the provider help with entity setup, employee transfer, and continuity of benefits? If not, plan for the eventual switch cost.
Honest limits: what EOR cannot do for a biotech
The hub article on why medical companies use EOR covers this in detail. The biotech-specific summary is that EOR cleanly handles the great majority of cross-border hires a clinical-stage company makes, but it is not a workaround for licensure or sponsor-responsible-person rules.
Specifically, EOR generally cannot:
- Employ a clinical trial investigator named on a regulatory submission as the principal investigator. PI status sits with the licensed clinician at the trial site, under the investigator responsibilities framework, not with the sponsor's contractual employer.
- Hold a Qualified Person (QP) or Person Responsible for Regulatory Compliance (PRRC) designation under EU MDR Article 15 or the EU GMP framework; these roles attach to the regulated manufacturer, not to the employment vehicle. An EOR can employ a QP-credentialed individual, but the QP designation itself runs through the manufacturing authorization holder.
- Handle controlled-substance work in jurisdictions that require the employer to hold a DEA registration or equivalent national license. Schedule II to V handling, including some preclinical work, is regulated at the employer level.
- Employ US state-licensed clinical roles for direct patient-facing work, such as staff nurses, prescribing physicians, and similar. State scope-of-practice rules attach to the employer's registration with the state.
For most clinical-stage biotechs these limits are containable. PI agreements are handled through CRO and site contracts. QP and PRRC designations are arranged through the manufacturing partner or the regulatory consultancy. Controlled-substance work is concentrated at the CMO. The point is to know which roles need a different vehicle, and to not ask the EOR to solve a problem it structurally cannot solve.
A worked example
Consider a Series A oncology biotech with $80M raised, 22 US employees, and a Phase Ib starting in Q3 across Spain, Portugal, and Germany. The hiring plan calls for one CRA in each of the three countries, a regulatory affairs lead in Germany, and a biostatistician in Poland.
The entity-first approach: three to four entities, $80,000 to $150,000 in setup costs, six to nine months to first hire, and recurring annual overhead of roughly $40,000 to $60,000 per country. By the time the entities are ready, the trial has been delayed.
The EOR approach: five hires live within two to three weeks. No setup cost. Per-employee monthly fees in the $500 to $800 range, plus statutory employer contributions identical to what an entity would pay. Total all-in cost in year one is materially below the entity path. If the Phase Ib reads out poorly and the program shrinks, the biotech can wind down the international footprint in weeks rather than months.
This is the math that drives most clinical-stage international hiring through EOR. It is not a permanent solution, but it is the right solution for the stage.
FAQs
What is an EOR for a biotech startup?
An Employer of Record is a third party that legally employs a worker in a country on behalf of a biotech company that has no local entity. The EOR handles employment contracts, payroll, taxes, statutory benefits, and termination compliance. The biotech directs the work and pays the EOR a per-employee fee plus the loaded employment cost.
Why do biotechs prefer EOR over opening a local entity?
Speed, capital efficiency, and reversibility. Entity setup runs three to nine months and $15K to $50K+ before the first paycheck. EOR delivers a legal hire in days at no setup cost, and can be wound down quickly if a trial pivots. For clinical-stage companies, that combination is usually decisive.
What is the pre-funded payroll trap?
Some EOR providers require the client to deposit the upcoming month's payroll into a holding account before salaries are paid. That cash sits restricted, outside the operating account, and does not extend runway. Other providers, including Borderless AI, invoice in arrears so payroll cash stays on the client's balance sheet until billing.
Which biotech roles are most commonly hired via EOR?
Clinical research associates, CMC and quality leads, regulatory affairs specialists, and biostatistics or SAS programming. Medical writers, pharmacovigilance specialists, and HEOR roles round out the next tier.
When should a biotech graduate from EOR to its own entity?
Common thresholds are roughly 10 to 20 employees in a single country, signing a long-term lease, hiring a country GM, or preparing an S-1. Below those thresholds EOR is almost always cheaper and faster.
Can an EOR employ a principal investigator on a clinical trial?
Generally no. PI status attaches to the licensed clinician at the trial site under FDA and equivalent international rules. The EOR can employ trial-adjacent roles like CRAs and clinical project managers, but not the PI themselves.
Is EOR cheaper than 1099 contractors for a biotech?
1099 contracting looks cheaper on a unit basis but carries misclassification risk under the 2024 DOL final rule, which is sharply enforced in healthcare. For most directed, integrated biotech roles (CRAs, regulatory leads, biostats), contractors fail the economic-realities test and create back-tax, overtime, and benefits liability. EOR removes the question.
Further reading
- Why Medical Companies are Turning to Employer of Record services
- How to Hire Clinical Research Associates Globally
- How Medical Device Companies are Staffing Rollouts
- Hiring Medical Science Liaisons Internationally
- Global Hiring for Digital-Health and Telemedicine Companies
- How Tech Companies Are Turning to Employer of Record Services
Where this leaves a clinical-stage biotech
A tight runway does not eliminate the need to hire across borders; it makes the way you hire matter more. Entity setup is a poor fit for the first hires in any country. Pre-funded payroll quietly converts working capital into restricted cash. The right EOR shape is owned entities in the countries that match your trial and CMC footprint, in-arrears payroll, and a clean migration path once any one country grows past the EOR-versus-entity crossover.
For a deeper view of the sector context, the hub article on why medical companies use EOR covers the demographic, regulatory, and capital pressures driving the shift. For the role-specific playbooks, see the companion spokes on hiring CRAs globally, hiring MSLs internationally, and the healthcare misclassification problem.
If you are evaluating EOR for a clinical-stage workforce, Borderless AI's healthcare team is built for the cash-and-speed conversation, not a generic demo.
